Release Date: September 25, 2025
Expiration Date: September 25, 2026
Activity Overview
The characterization of the RAS oncogenes and mutations that lead to their activation has been one of the seminal discoveries in oncology. However, actively exploiting these proteins as a therapeutic strategy in solid tumor oncology has been made possible only recently with the incorporation of highly specific inhibitors. More recently, novel RAS-directed strategies have been developed, with the potential to address a much wider range of RAS alterations.
This educational meeting, provided in conjunction with the 2025 International Symposium of Gastrointestinal Oncology, brings together world-leading faculty in the management of gastrointestinal cancers to discuss the current landscape of agents targeting RAS family members, as well as novel strategies in development with the potential to impact a much broader range of alterations.
This educational activity is an archive of the live virtual symposium held on September 12, 2025.
Target Audience
This educational activity is directed toward medical oncologists and practitioners of oncology subspecialties, along with surgeons, radiologists, general scientists, young investigators, nurses, and pharmacists with an interest in gastrointestinal (GI) oncology. Other health care professionals interested in the treatment of these malignancies are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the current and emerging role of RAS-directed therapies across GI malignancies
- Identify appropriate molecular profiling tests to individualize patient treatment therapies for patients with GI cancers
- Analyze efficacy and safety data from RAS-directed clinical trials and their impact on the management of GI cancers
- Implement optimal approaches for incorporating innovative RAS therapies into the treatment of GI cancers where approved
- Apply proactive strategies for monitoring and managing treatment-related toxicities in patients receiving RAS-directed therapies for GI cancers
John H. Strickler, MD
Professor of Medicine, Division of Medical Oncology
Duke University School of Medicine
Coleader, Precision Cancer Medicine and Investigational Therapeutics Program
Duke Cancer Institute
Durham, NC
Disclosures: Advisor/Consultant/Speaker/Honoraria Recipient: AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BeOne, Bristol Myers Squibb, Cytovation, Daiichi Sankyo, Eli Lilly, GE Healthcare, GSK, Incyte, Ipsen, Jazz Pharmaceuticals, Johnson & Johnson, Leap Therapeutics, Merck, Natera, Pfizer, Quanta Therapeutics, Regeneron, Roche/Genentech, Sanofi, Taiho, Takeda, Xilio Therapeutics; Grant/Research Support: AbbVie, Amgen, Apollo Therapeutics, Bayer, BeOne, Daiichi Sankyo, Eli Lilly, GSK, Leap Therapeutics, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, Roche/Genentech; Ownership interests in privately held companies: Triumvira Immunologics.
Tanios S. Bekaii-Saab, MD
David F. and Margaret T. Grohne Professor of Novel Therapeutics for
Cancer Research I
Chair, Division of Hematology and Medical Oncology
Mayo Clinic in Arizona
Phoenix, AZ
Disclosures: Grant/Research Funding (to institution): AbGenomics, Agios, Arcus, Arys, Atreca, Bayer, Boston Biomedical, Bristol Myers Squibb, Celgene, Clovis, Eisai, Genentech, Incyte, Ipsen, Lilly, Merus, Mirati, Novartis, Pfizer, Seattle Genetics; Consulting (to institution): Arcus, Bayer, Eisai, Genentech, Incyte, Ipsen, Merck, Merus, Pfizer, Revolution Medicines, Seattle Genetics, Servier; Consulting (to self): AbbVie, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Caladrius Biosciences, Celularity, Daiichi Sankyo, Deciphera, Exact Sciences, Exelixis, Foundation Medicine, GSK, Illumina, Janssen, Kanaph, Natera, Sanofi, Sobi, Stemline, Takeda, Treos Bio, Xilio, Zai Lab; Independent Data Monitoring Committee/Data and Safety Monitoring Board: 1Globe, AstraZeneca, Exelixis, FibroGen, Merck/Eisai, PanCAN; Suzhou Kintor, The Valley Hospital; Scientific Advisory Board: Artiva, Immuneering, Imugene, Replimune, Sun Biopharma, Xilis; Royalties: UpToDate; Inventions/Patents: WO/2018/183488: Human PD1 Peptide Vaccines and Uses Thereof: licensed to Imugene; WO/2019/055687: Methods and Compositions for the Treatment of Cancer Cachexia: licensed to Recursion.
Bassel F. El-Rayes, MD
Professor of Medicine
Albert F. LoBuglio Endowed Chair for Translational Cancer Research
Division Director, Hematology and Oncology
Deputy Director, O’Neal Comprehensive Cancer Center
Heersink School of Medicine
University of Alabama at Birmingham
Birmingham, AL
Disclosures: Advisor/Consultant/Speaker/Honoraria Recipient: AstraZeneca, BeOne, Boehringer Ingelheim, Exelixis, Revolution Medicines; Grant/Research Funding: AstraZeneca, Boehringer Ingelheim, ProDa BioTech.
Ignacio Garrido-Laguna, MD, PhD, MBA
Professor of Oncology
University of Utah School of Medicine
Director, Phase 1 Program
Coleader, Gastrointestinal Oncology Multidisciplinary Disease Group
Huntsman Cancer Institute
Salt Lake City, UT
Disclosures: Advisor/Consultant/Speaker/Honoraria Recipient: AbbVie, Fortvita, Kestrel Therapeutics, Lilly, Quanta Therapeutics, Revolution Medicines, SOTIO; Grant/Research Funding (to self): EcoR1, Guidepoint; Grant/Research Funding (to institution): 280 Bio, ABM Therapeutics, Bayer, BridgeBio, Bristol Myers Squibb, GSK, Incyte, Jacobio, Lilly, MedImmune, Novartis, Pfizer, Quanta Therapeutics, Repare Therapeutics, Revolution Medicines, Sumitomo Dainippon Pharma Oncology, Tango, Tolero, Yingli.
Eileen M. O’Reilly, MD, FASCO
Winthrop Rockefeller Endowed Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers
Chair, Human Research Protection Program & IRB
Co-Director Medical, David M. Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY
Disclosures: Grant/Research Funding: AbbVie, Agenus, Arcus, AstraZeneca, Atara, BeiGene, BioNTech, Bristol Myers Squibb, Coherus, Digestive Care, Elicio, Genentech/Roche, Helsinn, J-Pharma, Parker Institute, Pertzye, Yiviva; Consulting: AbbVie, Ability, Agenus, Alligator Bioscience, Astellas, Arcus, AstraZeneca, Autem, Berry Genomics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, FibroGen, Genentech/Roche, Ipsen, J-Pharma, Merck, Merus, MOMA Therapeutics, Neogene, Novartis, Regeneron, Revolution Medicines, Servier, Syros, Tango, Tempus, Vector, Yiviva.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here